Abstract. The aim of the present study was to investigate the biological role and molecular mechanism of the deleted in liver cancer-1 (DLC-1) gene in human colon cancer growth and invasion. Recombinant lentiviral vectors encoding the DLC-1 gene were constructed for transfection into the human colon cancer cell line SW480. Real-time quantitative polymerase chain reaction (real-time qPCR) and western blot analysis were employed to evaluate the expression of DLC-1, β-catenin, GSK-3β and c-myc in DLC-1-transfected cells. Moreover, cell proliferation assay, cell colony formation assay, cell cycle analysis, apoptosis analysis and cell migration and invasion assays were performed in order to elucidate the role of DLC-1 in colorectal cancer development and progression. Both real-time qPCR and western blot analyses showed that the DLC-1 gene and protein were overexpressed in the DLC-1-transfected SW480 cells. In addition, the expression of β-catenin and GSK-3β was upregulated and the expression of the c-myc gene was downregulated in the DLC-1-transfected SW480 cells. Furthermore, DLC-1 overexpression inhibited cell proliferation, colony formation, migration and invasion, and induced cell cycle arrest at the G1 phase with subsequent apoptosis. DLC-1 inhibits cell growth and invasion in human colon cancer, functioning as a tumor-suppressor gene, possibly through the regulation of the Wnt/β-catenin signaling pathway.
Introduction
Colorectal cancer (CRC) is one of the most common malignancies and is the leading cause of cancer-related mortality, posing a major public health concern worldwide (1). In Asia, the overall CRC cure rate has not improved dramatically in the last decade with the 5-year survival rate at ~60% (2) . Over the past decades, a number of the critical mutations in key signaling pathways underlying the initiation and development of CRC have been shown to be associated with the regulation of cellular metabolism, proliferation, differentiation and survival (4, 5) . However, despite the fact that much progress has been made in the therapeutic management of CRC, patient prognosis still remains poor due to disease recurrence and metastasis. Therefore, elucidation of mechanisms underlying CRC occurrence and development is needed in order to develop novel therapeutic approaches to CRC. Over the years, genetic changes responsible for CRC recurrence and metastasis have also been extensively explored. Although a large number of genetic changes have been documented, there are still many molecular aspects of colorectal tumorigenesis that must be elucidated (3) (4) (5) .
The deleted in liver cancer-1 (DLC-1) gene, also called StAR-related lipid transfer protein 12 (STARD12), is a novel candidate tumor-suppressor gene located on human chromosome 8p21-22 (6) . This region harbors a number of tumor-suppressor genes, and loss of heterozygosity (LOH) in this region is frequently detected in a variety of human cancers, including CRC (5, (7) (8) (9) (10) (11) . It has been suggested that DLC-1 may inhibit cell proliferation and induce cell apoptosis in human cancer via regulation of cyclin D1 expression which acts downstream of β-catenin (12) . It is well known that β-catenin is a key factor in the Wnt/β-catenin signaling pathway (13) . Furthermore, it has been shown that cyclin D1 expression is associated with β-catenin expression and correlates with favorable prognosis in CRC (14) . Moreover, the initiating event in tumorigenesis of most CRCs is the aberrant activation of the Wnt/β-catenin signaling pathway (15) . Mutations in the components of the Wnt signaling pathway, such as the adenomatous polyposis coli (APC) gene and the β-catenin gene (CTNNB1), play important roles in initiation and development of CRC (16) . Since both DLC-1 and the Wnt pathway are associated with CRC, DLC-1 may interact with the Wnt pathway in colorectal carcinogenesis. In the present study, we aimed to investigate the role of DLC-1 in tumor growth and invasion as well as to explore its possible interactions with the Wnt signaling pathway. The DLC-1 effects on cell growth and invasion were examined in a DLC-1-transfected colon cancer cell line SW480. In addition, in CRC cells overexpressing DLC-1, the role of the Wnt/β-catenin pathway components (β-catenin, GSK-3β and c-myc) in cell growth and invasion was investigated to further establish the relationship between DLC-1 and the Wnt/β-catenin pathway.
Materials and methods
Cell culture and transfection reagents. The pcDNA3.1(+)-GFP plasmid, oligo DNA, Pfu DNA polymerase, packaging plasmids (pHelper1.0/pHelper2.0), lentiviral vectors and other routine molecular reagents were purchased from Gemma Co., Ltd. (Shanghai, China). Plasmid and DNA isolation/purification kits were purchased from Qiagen (Shanghai, China). T4 DNA ligase and restriction enzymes were purchased from Fermentas Co. (Thermo Fisher Scientific, Waltham, MA, USA). Lipofectamine™ 2000 and TRIzol were purchased from Invitrogen (Carlsbad, CA, USA). Culture medium Dulbecco's modified Eagle's medium (DMEM) was purchased from HyClone (Logan, UT, USA). Fetal bovine serum (FBS) and other culture-related materials were purchased from Gibco (Carlsbad, CA, USA). The human colon cancer SW480 cell line, packaging cell lines Top10 and 293T were provided by The Key Laboratory of Surgery, Chongqing Medical University (Chongqing, China) and were cultured in DMEM supplemented with 15% FBS and maintained in a humidified incubator at 37˚C with 5% CO 2 .
Construction of the expression plasmid and the lentiviral vector.
A full-length DLC-1 cDNA was subcloned into the pcDNA3.1(+)-GFP plasmid by using T4 DNA ligase, constructing the recombinant plasmid pcDNA3.1(+)-GFP-DLC-1. The sequence and orientation of the vector inserts were confirmed by restriction enzyme digestion and DNA sequencing. Next, competent cell line Top10 was transfected with the recombinant plasmid using Lipofectamine 2000, according to the manufacturer's instructions. The transfected Top10 cells were cultured in ampicillin plates for 16 h. Positive cell clones were selected and cultured overnight. The recombinant plasmid was amplified in the Top10 competent cells. Restriction analysis with BamHI and NotI enzymes and DNA sequencing were used to confirm the true cloning of DLC-1.
Recombinant plasmids pcDNA3.1(+)-GFP-DLC-1 and the packaging vectors (15 µg of pHelper1.0 and 10 µg of pHelper2.0) were extracted respectively by highly purified and non-toxic extraction. The 293T cells in the exponential phase of growth were seeded into 6-well plates containing DMEM supplemented with 10% FBS at 6x10 5 /ml. Recombinant lentiviruses were packaged by transfecting the 293T cell line with 20 µg of pcDNA3.1(+)-GFP-DLC-1, 15 µg pHelper1.0 and 10 µg pHelper2.0 using 100 µl of Lipofectamine 2000, according to the manufacturer's instructions. A negative control was constructed by transfecting the 293T cell line with the pcDNA3.1(+)-GFP plasmid. The medium was replaced with 25 ml of complete medium 8 h after transfection and cultured at 37˚C in a humidified incubator with 5% CO 2 . Forty-eight hours after transfection, cells were collected, and centrifuged at 12,000 x g for 3 h. Supernatant cells were filtered through a PVDF membrane and kept in an ice bath overnight. The transient expression of green fluorescent protein (GFP) in the transfected cells was detected by fluorescence microscopy. Virus titers of the lentiviral vectors were determined by fluorescence microscopy and flow cytometry (TU/ml).
Colon cancer cell line transfection. SW480 cells were seeded in 6-well plates at a concentration of 1x10 5 cells/well, and maintained at 37˚C in a humidified 5% CO 2 incubator overnight. One hundred microliters of lentivirus fluid was diluted 10-fold with DMEM containing 15% FBS, and 5 µg/ml polybrene was added. The medium in 6-well plates was extracted and 1 ml of lentivirus fluid was added to each well, cultured at 37˚C in a humidified 5% CO 2 incubator for 24 h. Next, the lentivirus fluid in the 6-well plates was removed, and 1 ml of fresh DMEM was added to each well for cultivation at 37˚C in a humidified 5% CO 2 incubator for 48 h. The cells with positive GFP were screened, selected and amplified in culture bottles to construct stable cell lines. The infection rate was determined using fluorescence microscopy and flow cytometry. Negative controls were performed by transfecting the SW480 cell line with the pcDNA3.1(+)-GFP lentiviral vector, and untransfected SW480 cells were used as a blank control in all experiments.
Real-time PCR. Total RNA from cells in the exponential phase of growth was extracted by use of TRIzol reagent, according to the manufacturer's instructions. After being treated with DNase-I, 1 mg of total RNA was reverse transcribed into complementary DNA (cDNA) with oligo(dT) using a cDNA synthesis kit (OriGene Technologies, Inc., Rockville, MD USA). RNA purity and integrity were determined by the OD value and electrophoresis. Real-time PCR primers (designed by Gemma Co., Ltd.) were as follows: DLC-1, 5'-CCGCCTG AGCATCTACGA-3' (forward) and 5'-TTCTCCGACCACT GATTGACTA-3' (reverse); GSK-3β, 5'-GAACTGTCAAGTA ATCCACCTCTG-3' (forward) and 5'-CCACGGTCTCCAGT ATTAGCATC-3' (reverse); β-catenin, 5'-CTGCCAAGTGGG TGGTATAGAG-3' (forward) and 5'-CGGGACAAAGGG CAAGAT-3' (reverse); c-myc, 5'-GCTGCTTAGACGCTGG ATTT-3' (forward) and 5'-CGAGTCGTAGTCGAGGTC ATAGTT-3' (reverse); GAPDH, 5'-CATGAGAAGTATGAC AACAGCCT-3' (forward) and 5'-AGTCCTTCCACGATACCA AAGT-3' (reverse).
The PCR conditions were as follows: initial denaturation at 95˚C for 3 min, followed by 40 cycles of 95˚C for 30 sec, 62˚C for 40 sec and 72˚C for 30 sec. After 40 cycles of PCR amplification, dissociation analysis was performed by melting the products from 60 to 95˚C. All reactions were performed using a real-time PCR kit (DAAN Gene Co., Ltd., Guangzhou, China). Real-time PCR was carried out in triplicate. The human GAPDH gene was chosen as the endogenous control according to a preliminary experiment, and the expression levels of four target genes (DLC-1, GSK-3β, c-myc and β-catenin) were examined. The relative gene expression levels were calculated using the ΔΔCt method.
Western blot analysis. Total cell proteins were isolated using protein sample extraction reagent. Equal amounts of protein were separated on SDS-PAGE gels and transferred onto PVDF membranes. Membranes were blocked with 5% w/v skimmed milk in 0.1% Tween-20 for 1 h and incubated with primary antibodies (1:1,000) at 4˚C overnight before incubation with the secondary antibodies (1:1,000) for 1 h at room temperature. The following antibodies were used: DLC-1 (15460-1-AP, PTG) 1:1,000, GSK-3β (51065-1-AP, PTG) 1:1,000, β-catenin (51067-2-AP, PTG) 1:2,000, c-myc (10828-1-AP, PTG) 1:500, GAPDH (Sigma G8795) 1:12,000, HRP-conjugated goat anti-mouse IgG (JIR 115-035-003) 1:5,000 and HRP-conjugated goat antirabbit IgG (JIR 111-035-003) 1:5,000. Specific proteins were visualized using the SuperSignal West Pico Chemiluminent Substrates system (Thermo Fisher Scientific) and were then exposed with Kodak X-ray film. Protein band intensities were determined densitometrically using the Gel-Pro analyzer software (Media Cybernetics, Inc., Rockville, MD, USA). All experiments were performed in triplicate.
Cell proliferation assay. Transfection was performed when the cells reached 70-90% confluency. Cell proliferation was measured by a methylthiazol tetrazolium (MTT) assay. Fortyeight hours after transfection, cells were cultured at a density of 5x10 3 cells/well in triplicate in 96-well plates with 10% FBS at 37˚C and 5% CO 2 . The MTT assay was performed daily for up to 5 days. Briefly, 10 µl of CCK-8 solution [Cell Counting Kit (CCK-8); Qcbio S&T Co., Ltd., Shanghai, China] was added to each well and maintained in an incubator at 37˚C with 5% CO 2 for 1 h. The absorbance of each well was determined at 450 nm using a microtiter plate reader (Molecular Devices, Sunnyvale, CA, USA). The CCK-8 values were detected every 24 h, and the results are expressed as the mean ± SD of three independent experiments.
Colony formation assay. Cells in the exponential phase of growth were selected and suspended into single cells by pipetting, and then inoculated into 10-cm Petri dishes. The cell suspension was further diluted with a gradient factor. Approximately 500 cells were added to the Petri dishes which were incubated at 37˚C for 2-3 weeks until visible colonies appeared. Petri dishes were gently washed twice with PBS. Colonies were fixed with 5 ml methanol for 15 min, stained with Giemsa for 10-30 min, and then counted. Viable colonies containing at least 50 cells were counted.
Cell cycle analysis. The cells in the exponential phase of growth were centrifuged at 1,200 x g for 5 min, washed twice with PBS, and fixed with 70% ethanol at -20˚C for 12 h. Cells were then centrifuged and collected. Cells were digested with 50 µg/ml of RNAase A in 100 µl of PBS for 30 min at room temperature and then stained with 5 µl of propidium iodide (PI) (SunShine Bio, Guangzhou, China) at room temperature for 30 min in the dark. Samples were then analyzed by flow cytometry.
Analysis of apoptosis.
The cells in the exponential phase of growth were digested with the pancreatic enzyme, trypsin. After being washed twice with cold PBS, the cells were collected by centrifugation, and mixed with 400 µl of 1X binding buffer, and then the 5 µl of Annexin V-FITC (Sunshine Bio) was added and incubated at 2-8˚C in the dark for 5 min, and subsequently 10 µl of PI was added and incubated at 2-8˚C in the dark for 5 min. Cell apoptosis was detected by flow cytometry.
Migration assay. Transwell chambers were used to detect the migratory ability of cells. The cells were detached, counted, and re-suspended in culture medium containing 2% FBS at a cell density of 10 6 /ml. One hundred microliters of cell suspension was added into each well in the upper Transwell chamber. Five hundred microliters of culture medium containing 10% FBS was added to the 24-well plate in the lower Transwell chamber, and incubated for 24 h. The Transwell chamber was taken out and washed twice with PBS. The cells on the surface of the Transwell chamber were wiped off with cotton swabs. The cells were then fixed with methanol for 30 min and stained with Giemsa for 10 min. The cells that remained at the bottom side of the membrane were counted under a microscope in five random visual fields.
Invasion assay. Transwell chambers were used for detecting the invasive ability of cells. Fifty microliters of 25% BD Matrigel/75% serum-free medium mixture was added to the upper chambers and incubated at 37˚C with 5% CO 2 . SW480 cells (100 ml of 1x10 6 /ml) were added to the upper chamber, and 500 µl of 20% FBS was added to the lower chamber. After a 24-h incubation, the chamber was washed twice with PBS, and the cells remaining on the upper surface of the membrane were removed using cotton tips. Cells that adhered to the underside of the membrane were fixed with methanol for 30 min and stained with Giemsa for 30 min. Cells in five random visual fields were counted.
Statistical analysis. All data are representative of at least three independent experiments. For continuous variables, data are expressed as mean ± standard error of the mean (SEM). The difference among groups was determined by analysis of variance (one-way ANOVA) followed by Newman-Keuls post-hoc study. Comparison of rates were analyzed using the Chisquared test. Comparison of mRNA and protein expression levels among groups was analyzed using the non-parametric Wilcoxon signed-ranks test. SPSS Statistics 19.0 was used for statistical analysis. Statistical significance was defined as P<0.05.
Results
Plasmid preparation and identification. As a confirmatory step to evaluate recombinant plasmid integrity, the recombinant plasmid pcDNA3.1(+)-GFP-DLC-1 was digested with BamHI and NotI restriction enzymes. As expected, a two band pattern appeared after being progressed on 1% agarose gel (Fig. 1A) . DNA sequencing showed that the full length of DLC-1 was completely and correctly cloned into the recombinant plasmid vector (Fig. 1B) . This confirmed that the recombinant plasmid pcDNA3.1(+)-GFP-DLC-1 was correctly constructed.
Identification and quantification of recombinant lentiviral vectors. After transfection, the 293T cell line was evaluated to detect the presence of green fluorescent protein emission under microscopy. The fluorescent signal from the 4th day to the 6th day after transfection served as evidence of vector production (Fig. 2) . After the purification of the virus, the titer of the recombinant viral stocks was evaluated. The results indicated that the titers of both the recombinant virus and the negative control were ~109 TU/ml.
Transduction and infectivity analysis. The human colon cancer cell line SW480 was infected with the recombinant lentiviral vectors and blank lentiviral vectors, respectively. GFP protein expression was detected by microscopy 72 h after infection (Fig. 3) . Flow cytometric analysis showed expression of GFP in >90% of live cells in the assessed samples i.e. the infectivity was 90%. As shown in Fig. 4A , the relative DLC-1 mRNA expression in the untransfected SW480 group, the pcDNA3.1(+) group and the pcDNA3.1(+)-DLC-1 group was 0.80 (0.78-0.81), 1.00 (0.98-1.02) and 23.32 (21.97-24.75), respectively. DLC-1 mRNA expression in the pcDNA3.1(+)-DLC-1 group was significantly higher than levels in the pcDNA3.1(+) group and untransfected SW480 group (P<0.01). There was no statistically significant difference in the DLC-1 mRNA expression between the pcDNA3.1(+) group and the untransfected SW480 group (P>0.05).
DLC-1 overexpression in the transfected
Western blot analysis was performed 96 h after infection. Relative DLC-1 protein expression in the untransfected SW480 group, the pcDNA3.1(+) group and the pcDNA3.1(+)-DLC-1 group was 0.91±0.04, 0.89±0.06 and 2.19±0.16, respectively. DLC-1 protein expression in the pcDNA3.1(+)-DLC-1 group was significantly higher than that of the pcDNA3.1(+) group and the untransfected SW480 group (P<0.01), while there was no statistically significant difference between the untransfected SW480 group and the pcDNA3.1(+) group (P>0.05). (Fig. 5A) . Cell proliferation activity of the pcDNA3.1(+)-DLC-1 group was gradually inhibited from the second day after transfection, and as time passed, the cell proliferation activity of this group was significantly decreased compared with the pcDNA3.1(+) group and the untransfected SW480 group (P<0.05). In addition, there was no significant difference between the proliferation of the untransfected SW480 group and the pcDNA3.1(+) group (P>0.05), which suggested that DLC-1 overexpression may inhibit the proliferation of colon cancer cells. Moreover, a significant decrease was observed in the colony formation of the pcDNA3.1(+)-DLC-1 group when compared to the pcDNA3.1(+) group and the untransfected SW480 group (P<0.01) (Fig. 5B and C) .
DLC-1 overexpression inhibits proliferation and colony formation of SW480 cells. Absorbance of transfected cells was detected every 24 h, from 24 to 72 h after transfection

DLC-1 overexpression influences cell cycle progression.
Flow cytometry showed that the pcDNA3.1(+)-DLC-1 cell group was arrested at the G1 phase. Thus, DLC-1 overexpression influences the progression of colon cancer cells through the cell cycle (Fig. 6) .
DLC-1 overexpression induces apoptosis in SW480 cells.
The rate of apoptosis of the pcDNA3.1(+)-DLC-1 group was determined by flow cytometry and was significantly higher than that of the untransfected SW480 group and the pcDNA3.1(+) group (P<0.01). No difference was observed between the untransfected SW480 group and the pcDNA3.1(+) group (P>0.05) (Fig. 7) .
DLC-1 overexpression inhibits migration of SW480 cells.
As shown in Fig. 8 , the number of cells that migrated in the Transwell migration assay was 56.00±4.53, 53.00±3.54 and 21.80±2.59 in the untransfected SW480 cells, the pcDNA3.1(+) cells and the pcDNA3.1(+)-DLC-1 cells, respectively. The number of cells from the pcDNA3.1(+)-DLC-1 group that passed through the membrane was significantly lower than the number of cells from the pcDNA3.1(+) group or the untransfected SW480 group (P<0.01). No difference was observed between the untransfected SW480 group and the pcDNA3.1(+) group (P>0.05). These results show that DLC-1 overexpression inhibits the migratory ability of colon cancer cells.
DLC-1 overexpression inhibits the invasion of SW480 cells.
The number of cells that invaded through Matrigel in the Transwell invasion assay was 10.80±1.64, 11.00±1.58 and 2.00±0.71 for the untransfected SW480 group, the pcDNA3.1(+) group and the pcDNA3.1(+)-DLC-1 group, respectively (Fig. 9) . The number of cells from the pcDNA3.1(+)-DLC-1 group that passed through the membrane was significantly lower than that of the pcDNA3.1(+) group and the untransfected SW480 group (P<0.01). No significant difference was observed between the untransfected SW480 cells and the pcDNA3.1(+) group (P>0.05). These results showed that DLC-1 overexpression inhibits the invasive ability of colon cancer cells.
DLC-1 overexpression regulates the Wnt/β-catenin signaling pathway.
Real-time PCR showed that GSK-3β mRNA expression in the pcDNA3.1(+)-DLC-1 group was significantly higher than that in the pcDNA3.1(+) group and the untransfected group (P<0.0001). The β-catenin mRNA expression was significantly lower than that in the pcDNA3.1(+) group and the SW480 cells (P<0.0001). The c-myc mRNA expression level was significantly lower than that in the pcDNA3.1(+) group and the SW480 group (P<0.0001).
The results of the western blot analysis showed that the expression level of GSK-3β protein was significantly higher than that in the pcDNA3.1(+) group and the SW480 group (P<0.0001). The β-catenin protein expression level was significantly lower than that in the pcDNA3.1(+) group and the SW480 group (P<0.0001). The c-myc protein expression level was significantly lower than that in the pcDNA3.1(+) group and the SW480 group (P<0.0001).
As shown in Fig. 10 , GSK-3β mRNA expression was upregulated, while the expression of both β-catenin and c-myc mRNA was downregulated. The results of western blot analysis confirmed these findings at the protein expression level. Therefore, DLC-1 overexpression upregulates GSK-3β, and downregulates mRNA and protein expression of β-catenin and c-myc.
Discussion
CRC is the third most common cancer and the fourth leading cause of cancer-related mortality worldwide (17) . Surgical resection alone is potentially curative in early stages of CRC. Unfortunately, most CRCs are in advanced stages at the time of diagnosis. Although new therapies with monoclonal antibodies such as cetuximab and panitumumab, which target the epidermal growth factor receptor (EGFR), have had some clinical success (16) , metastasis still remains a huge problem and the prognosis of patients with metastatic CRC still remains dismal. As accumulating evidence has shown, mutations in a number of genes and dysregulation of the Wnt/β-catenin signaling pathways are closely related to colorectal carcinogenesis. Through dysregulation of this signaling pathway and crosstalk with other cellular signaling pathways, continuous growth-stimulating signals induce changes in the pre-cancerous cells themselves as well as in their microenvironment. In this process, β-catenin plays an important role (4, 5, 15, 18, 19) . Many genetic markers in CRC have promising potential for use in the treatment selection, prognosis, and early detection of cancer (16) . Therefore, a detailed understanding of genetic mutations in colorectal carcinogenesis is essential to develop new approaches to cure CRC and prevent tumor recurrence.
Recent studies have shown that both the DLC-1 gene and the Wnt/β-catenin signaling pathway play critical roles in CRC (20) (21) (22) (23) (24) (25) . DLC-1 is a candidate tumor-suppressor gene which induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells (26) . Another study showed that DLC-1 suppresses cell growth and invasion in lung cancer (27) . Jin et al (28) found that decreased DLC-1 expression in the SW480 cell line promoted cell proliferation and migration and induced cell cycle arrest at the G2/M phase, suggesting that the DLC-1 gene is associated with colon cancer cell proliferation, migration and cell cycle distribution. A few similar studies on the DLC-1 gene have confirmed that DLC-1 acts as a tumor-suppressor gene in several malignant tumors (9) (10) (11) (12) 20) . However, although the role of DLC-1 during the pathogenesis of CRC has been suggested, the detailed molecular pathway and downstream targets have not yet been fully elucidated.
Research suggests that the tumor suppressor effects of DLC-1 relate to the expression of cyclin D1 (29) . Cyclin D1 is the target gene of the Wnt/β-catenin signaling pathway, and it is tightly related to β-catenin (30) . The Wnt signaling pathway is highly conserved in various species, controlling cell proliferation, cell polarity and cell fate among other activities. In addition, it has been shown that it is often dysregulated in a variety of diseases including cancer. Extensive studies have shown that the Wnt/β-catenin signaling pathway plays important roles in CRC (13, 31) . The Wnt signaling pathway consists of several key components such as Wnt proteins, β-catenin, glycogen synthase kinase-3β (GSK-3β) and APC protein (13, 32) . In normal intestinal mucosa, APC expression increases gradually from the bottom to the top of intestinal crypts (31, 34) . When the Wnt signaling pathway is inactive, a destruction complex consisting of APC, Axin and GSK-3β promotes β-catenin degradation, which causes a relatively low β-catenin protein level in intestinal cancer cells (13, 32, 33) . Mutations in the destruction complex components have been detected in many diseases including cancer (31) (32) (33) . APC mutations lead to inactivation of the destruction complex, resulting in an increased β-catenin level in the nucleus, which promotes expression of several target genes (13, 31, 33, 34) . In addition, functional defects in the destruction complex components inhibit apoptosis, breaking the balance of cell proliferation and differentiation, which results in formation of adenomatous polyps (35) (36) (37) .
In the present study, in order to examine the role of DLC-1 in CRC cell growth and invasion, we constructed a recombinant lentiviral vector coding DLC-1 and transfected the human colon cancer cell line SW480. Both DLC-1 mRNA and protein levels in the transfected SW480 cells were significantly upregulated. Next, we showed that DLC-1 overexpression inhibited cell proliferation, colony formation, migration and invasion but induced cell apoptosis and arrested the cell cycle at the G1 phase. Therefore, the results of the present study demonstrate that DLC-1 may act as a tumor-suppressor gene in colon cancer. Moreover, we analyzed the expression levels of the Wnt pathway components GSK-3β, β-catenin and c-myc gene by real-time PCR and western blot analysis. Collectively, these results show that DLC-1 overexpression suppresses the Wnt/β-catenin signaling pathway by upregulating GSK-3β, and downregulating β-catenin and c-myc. In addition, the results suggest that DLC-1 interacts with the Wnt/β-catenin signaling pathway. However, the exact details of this process are still unknown. Therefore, in forthcoming studies, our aim will be to elucidate the relationship between DLC-1 and the Wnt/β-catenin signaling pathway in colorectal cancer cells.
In conclusion, the results of the present study suggest that the tumor-suppressor gene DLC-1 may induce cell apoptosis, and inhibit both cell growth and invasion through regulation of the Wnt/β-catenin signaling pathway.
